Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 15,932 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 2 Clear all
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 6:28 PM EDT
Recruiting Phase 4 Interventional

Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy

NCT07287826
View directory record Official record
Conditions
Oral Mucositis Due to Chemotherapy
Interventions
Dexamethasone Mouthwash
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

One Step at a Time: An Intervention to Reduce Sedentary Behavior Among Working Adults

NCT05281978
View directory record Official record
Conditions
Sedentary Behavior, Exercise, Middle Age, Adult
Interventions
Decrease Sedentary Time + Increase MVPA group, Increase MVPA group
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
45 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 23, 2026, 6:28 PM EDT
Withdrawn Phase 2 Interventional

Allograft for Sickle Cell Disease and Thalassemia

NCT02038478
View directory record Official record
Conditions
Sickle Cell Disease and Thalassemia
Interventions
Donor Stem Cell Transplantation
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 23, 2026, 6:28 PM EDT
Not yet recruiting Phase 2 Interventional

Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT07756840
View directory record Official record
Conditions
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases, Tracheal Diseases, Respiratory Tract Neoplasm
Interventions
PRGN-2012, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RIGHT IV Pilot Study

NCT01792778
View directory record Official record
Conditions
Peripheral Intravenous Catheters
Interventions
ViaValve Safety IV Catheter, Insyte Autoguard BC [Blood Control] Shielded IV Catheter
Device
Lead sponsor
Smiths Medical, ASD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lakota Family Acceptance Project

NCT07326748
View directory record Official record
Conditions
LGBTQ, Racial Disparities, Family Relationships, Minority Stress, Depression, Anxiety, Drug Use, Teen Dating Violence, Sexual Risk Reduction
Interventions
Adapted Lakota Family Acceptance Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Pine Ridge, South Dakota • Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01823835
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0810, LHRH Agonist, Palbociclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 23, 2026, 6:28 PM EDT
Terminated Phase 2 Interventional Results available

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01913535
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Results available

Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC

NCT03567850
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Problem solving Skills Training
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Measuring Practice Pattern Changes and Clinical Utility of a Novel Test for Preeclampsia

NCT04204018
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Experimental Arm
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 23, 2026, 6:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)

NCT00880555
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 89 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

NCT01000285
View directory record Official record
Conditions
Leukemia-Lymphoma, Adult T-Cell
Interventions
Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 23, 2026, 6:28 PM EDT
Terminated Phase 1 Interventional

Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers

NCT02268825
View directory record Official record
Conditions
Advanced GI Cancer
Interventions
MK-3475
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional

Listening to Mom in the NICU: Neural, Clinical and Language Outcomes

NCT02847689
View directory record Official record
Conditions
Premature Birth
Interventions
Language Treatment, Control Treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
24 Weeks to 31 Weeks
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 6:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

NCT06376565
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Communication Intervention, Interview
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03038100
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Paclitaxel, Carboplatin, Atezolizumab, Bevacizumab, Atezolizumab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
127
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 23, 2026, 6:28 PM EDT
Terminated Phase 1 Interventional

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611
View directory record Official record
Conditions
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 6:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 23, 2026, 6:28 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Interventions
Coformulated favezelimab/pembrolizumab, Coformulated vibostolimab/pembrolizumab, EV, Pembrolizumab
Biological · Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
La Jolla, California • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 6:28 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 23, 2026, 6:28 PM EDT